This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Endocrine Diseases  • Thyroid/ Parathyroid Diseases  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Neurology  • Prognosis/ Outcomes  • Neurocutaneous Diseases  • Endocrine Disease of Head & Neck  • Alert me on articles by topic

Jason A. Smith, MD; Chun-Yang Fan, MD, PhD; Chunlai Zou, MD, MS; Donald Bodenner, MD, PhD; Mimi S. Kokoska, MD

Arch Otolaryngol Head Neck Surg. 2007;133(10):1006-1011.

Objectives  To determine the methylation status of gene promoter regions using methylation-specific polymerase chain reaction in genes encoding for thyrotropin receptor (TSHR), E-cadherin (ECAD), sodium iodide symporter protein (NIS-L), ataxia telangiectasia mutated (ATM), and death-associated protein kinase (DAPK) proteins and if methylation status correlates with patient variables, tumor factors, or outcome measures among patients with papillary thyroid carcinoma.

Design  Database query and retrospective medical chart review for patients with well-differentiated thyroid cancer and nonmalignant thyroid conditions treated at our institutions (1996-2004). Methylation-specific polymerase chain reaction was performed, and results were compared with controls for these genes. Methylation status was then compared with patient variables, tumor factors, and outcome measures for patients with thyroid carcinoma and controls.

Patients  The study population comprised 32 patients with papillary thyroid carcinoma and 27 controls.

Results  In our patients, all 5 genes were methylated more frequently in papillary thyroid carcinoma than in controls. NIS-L trended toward a more advanced stage at presentation. NIS-L methylation in cancer cells was not associated with methylation in adjacent benign tissue, unlike the other 4 genes. Neither age nor sex affected methylation status, and methylation status did not correlate with extent of the primary tumor or presence of nodal metastasis at diagnosis. Tumors recurred less frequently in patients with TSHR methylation than in patients with unmethylated TSHR promoter regions.

Conclusions  Promoter methylation may be a marker for malignancy in thyroid carcinoma. Furthermore, methylation status of tumors as determined by methylation-specific polymerase chain reaction may help in determining patient prognosis.

Author Affiliations: Otolaryngology, Surgical Services (Drs Smith and Kokoska), and Departments of Pathology (Drs Fan and Zou) and Geriatrics (Dr Bodenner), Central Arkansas Veterans Healthcare System, and Departments of Otolaryngology (Drs Smith and Kokoska), Pathology (Drs Fan and Zou), and Geriatrics (Dr Bodenner), University of Arkansas for Medical Sciences, Little Rock.